Skip to main content
. 2020 Sep 11;15(9):e0238913. doi: 10.1371/journal.pone.0238913

Table 1. Characteristics of study in the baseline.

Overall (n = 741,720) With CKD (n = 185,430) Without CKD (n = 556,290) P Standardized difference  Standardized mean difference
Variables n % n % n %
Gender 0.999 0.000 0.000
    Male 402,880 54.32 100,720 54.32 302,160 54.32
    Female 338,840 45.68 84,710 45.68 254,130 45.68
Age (years) 67.31 ± 13.55 67.30 ± 14.20 67.31 ± 13.33 0.783 -1.995 -0.363
Age groups (yrs) 0.999 0.000 0.000
    18–29 10,226 1.38 2,559 1.38 7,667 1.38
    30–39 24,428 3.29 6,107 3.29 18,321 3.29
    40–49 63,152 8.51 15,788 8.51 47,364 8.51
    50–59 111,160 14.99 27,790 14.99 83,370 14.99
    ≧60 532,744 71.83 133,186 71.83 399,558 71.83
Insured premium (NT$) <0.001*** -0.032 -0.002
    <18,000 732,832 98.80 183,435 98.92 549,397 98.75
    18,000–34,999 7,780 1.05 1,788 0.96 5,992 1.08
    ≧35,000 1,158 0.16 207 0.11 951 0.17
Comorbidities
    HTN 156,363 21.08 42,234 22.78 114,129 20.52 <0.001*** 0.023 0.001
    T2DM 144,996 19.55 63,178 34.07 81,818 14.71 <0.001*** 0.202 0.001
    HF 38,776 5.23 21,441 11.56 17,335 3.12 <0.001*** 0.084 0.001
    Stroke 69,462 9.36 13,180 7.11 56,282 10.12 <0.001*** -0.030 -0.001
    COPD 66,119 8.91 11,927 6.43 54,192 9.74 <0.001*** -0.003 -0.001
    Liver cirrhosis 41,886 5.65 10,910 5.88 30,976 5.57 <0.001*** 0.003 0.001
    Meniere's disease 13,890 1.87 1,434 0.77 12,456 2.24 <0.001*** -0.015 <0.001
CCI_R 1.24 ± 2.06 2.63 ± 1.61 0.77 ± 1.98 <0.001*** 1.942 0.005
Medications
    Aminoglycoside 4,585 0.62 600 0.32 3,985 0.72 <0.001*** -0.003 -0.001
    Loop diuretics 4,733 0.64 1,634 0.88 3,099 0.56 <0.001*** 0.004 0.001

P: Chi-square / Fisher exact test on category variables and t-test on continue variables.

*P < 0.05, **P < 0.01

***P < 0.001. CKD: chronic kidney disease, HTN: hypertension, T2DM: type 2 diabetes mellitus, HF: heart failure, COPD: chronic obstructive pulmonary disease.